These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36347212)

  • 21. Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data.
    Simon TA; Dong L; Winthrop KL
    Arthritis Res Ther; 2021 Jan; 23(1):17. PubMed ID: 33430948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses.
    Alves C; Penedones A; Mendes D; Batel-Marques F
    BMJ Open; 2020 Dec; 10(12):e041420. PubMed ID: 33384392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis.
    Song YK; Lee J; Jo J; Kwon JW
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
    Harigai M; Honda S
    Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
    Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
    Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis.
    Li N; Gou ZP; Du SQ; Zhu XH; Lin H; Liang XF; Wang YS; Feng P
    Clin Rheumatol; 2022 Mar; 41(3):677-688. PubMed ID: 34993729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors.
    Kato M
    Immunol Med; 2020 Jun; 43(2):72-78. PubMed ID: 32338187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
    Kim YE; Kim YJ; Jeong DH; Kim S; Kim MJ; Kim HH; Jo KW; Park SH; Hong S
    Semin Arthritis Rheum; 2024 Apr; 65():152362. PubMed ID: 38281468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case-control study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Sung YK
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 35091461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital.
    Ramirez Huaranga MA; Calvo Pascual LA; Velasco Sanchez D; Martin de la Sierra Lopez L; Jimenez Rodriguez L; Lopez Menchero Mora A; Castro Corredor D; Gonzalez Peñas M
    Cureus; 2024 Aug; 16(8):e67729. PubMed ID: 39318929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of peficitinib in rheumatoid arthritis.
    Kaneko Y
    Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
    Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
    Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC; Hider SL; Scott DL
    Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
    Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
    Atzeni F; Gozza F; Riva A; Alciati A; Galloway J
    Expert Opin Pharmacother; 2023 Apr; 24(6):679-689. PubMed ID: 36946287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.